The University of Chicago Header Logo

Connection

Mary Rinella to Non-alcoholic Fatty Liver Disease

Back to Details
This is a "connection" page, showing publications Mary Rinella has written about Non-alcoholic Fatty Liver Disease.
Mary Rinella
Connection Strength
30.618
Non-alcoholic Fatty Liver Disease
  1. Reply: 'From NAFLD to MASLD: Promise and pitfalls of a new definition' †. Hepatology. 2024 Feb 01; 79(2):E16-E17.
    View in: PubMed
    Score: 0.740
  2. From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease. J Lipid Res. 2024 Jan; 65(1):100485.
    View in: PubMed
    Score: 0.740
  3. Nonalcoholic steatohepatitis diagnosis and treatment from the perspective of patients and primary care physicians: a cross-sectional survey. Ann Med. 2023 12; 55(1):2211349.
    View in: PubMed
    Score: 0.738
  4. Reply: A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2024 Mar 01; 79(3):E93-E94.
    View in: PubMed
    Score: 0.736
  5. Pioneering the path to NASH biomarker approval. Nat Med. 2023 10; 29(10):2416-2417.
    View in: PubMed
    Score: 0.729
  6. Pegozafermin for NASH - A Sprint to Start a Marathon. N Engl J Med. 2023 Sep 14; 389(11):1044-1046.
    View in: PubMed
    Score: 0.727
  7. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023 Dec 01; 78(6):1966-1986.
    View in: PubMed
    Score: 0.716
  8. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023 12; 79(6):1542-1556.
    View in: PubMed
    Score: 0.716
  9. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol. 2024 Jan-Feb; 29(1):101133.
    View in: PubMed
    Score: 0.716
  10. Reply: People living with HIV and NAFLD and updated guidance on NAFLD screening. Hepatology. 2023 11 01; 78(5):E91-E92.
    View in: PubMed
    Score: 0.711
  11. Reply: ELF in the risk stratification of NAFLD-Are the ELF thresholds suggested by the AASLD guidelines appropriate? Hepatology. 2023 Dec 01; 78(6):E103-E104.
    View in: PubMed
    Score: 0.711
  12. Recurrent NAFLD post-LT: Sisyphus' boulder or Proteus' parable? Liver Transpl. 2023 09 01; 29(9):917-918.
    View in: PubMed
    Score: 0.707
  13. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023 05 01; 77(5):1797-1835.
    View in: PubMed
    Score: 0.702
  14. Extrahepatic Outcomes of Nonalcoholic Fatty Liver Disease: Nonhepatocellular Cancers. Clin Liver Dis. 2023 05; 27(2):251-273.
    View in: PubMed
    Score: 0.700
  15. Nonalcoholic steatohepatitis medical patient journey from the perspective of hepatologists, gastroenterologists and patients: a cross-sectional survey. BMC Gastroenterol. 2022 Jul 10; 22(1):335.
    View in: PubMed
    Score: 0.670
  16. Factors Impacting Survival in Those Transplanted for NASH Cirrhosis: Data From the NailNASH Consortium. Clin Gastroenterol Hepatol. 2023 02; 21(2):445-455.e2.
    View in: PubMed
    Score: 0.652
  17. Fatty Liver Disease: Diagnosis and Stratification. Annu Rev Med. 2022 01 27; 73:529-544.
    View in: PubMed
    Score: 0.641
  18. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. J Hepatol. 2022 03; 76(3):536-548.
    View in: PubMed
    Score: 0.640
  19. EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study. J Hepatol. 2022 03; 76(3):506-517.
    View in: PubMed
    Score: 0.639
  20. Non-alcoholic fatty liver disease. Lancet. 2021 06 05; 397(10290):2212-2224.
    View in: PubMed
    Score: 0.616
  21. The times they are a-changin' (for NAFLD as well). J Hepatol. 2020 12; 73(6):1307-1309.
    View in: PubMed
    Score: 0.589
  22. Real-World Burden of Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol. 2021 05; 19(5):1020-1029.e7.
    View in: PubMed
    Score: 0.583
  23. STELLAR 3 and STELLAR 4: Lessons from the fall of Icarus. J Hepatol. 2020 07; 73(1):9-11.
    View in: PubMed
    Score: 0.575
  24. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. Gastroenterology. 2020 05; 158(7):1851-1864.
    View in: PubMed
    Score: 0.567
  25. Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD. Hepatology. 2019 10; 70(4):1424-1436.
    View in: PubMed
    Score: 0.544
  26. Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD. J Hepatol. 2019 10; 71(4):823-833.
    View in: PubMed
    Score: 0.544
  27. Nonalcoholic Fatty Liver Disease: Identification and Management of High-Risk Patients. Am J Gastroenterol. 2019 04; 114(4):579-590.
    View in: PubMed
    Score: 0.534
  28. Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis. J Hepatol. 2019 04; 70(4):735-744.
    View in: PubMed
    Score: 0.522
  29. Editorial: Age and Non-Invasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease: Time to Adjust the Clock? Am J Gastroenterol. 2017 05; 112(5):752-754.
    View in: PubMed
    Score: 0.467
  30. Moderate Exercise for Nonalcoholic Fatty Liver Disease. JAMA Intern Med. 2016 08 01; 176(8):1083-4.
    View in: PubMed
    Score: 0.444
  31. The globalization of nonalcoholic fatty liver disease: Prevalence and impact on world health. Hepatology. 2016 07; 64(1):19-22.
    View in: PubMed
    Score: 0.434
  32. Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis. Dig Dis Sci. 2016 May; 61(5):1387-97.
    View in: PubMed
    Score: 0.431
  33. Management of NAFLD: a stage-based approach. Nat Rev Gastroenterol Hepatol. 2016 Apr; 13(4):196-205.
    View in: PubMed
    Score: 0.431
  34. Screening for nonalcoholic fatty liver disease in patients with atherosclerotic coronary disease?--In principle yes, in practice not yet. Hepatology. 2016 Mar; 63(3):688-90.
    View in: PubMed
    Score: 0.427
  35. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015 Jun 09; 313(22):2263-73.
    View in: PubMed
    Score: 0.410
  36. Impact of renal impairment on cardiovascular disease mortality after liver transplantation for nonalcoholic steatohepatitis cirrhosis. Liver Int. 2015 Dec; 35(12):2575-83.
    View in: PubMed
    Score: 0.409
  37. Nonalcoholic Fatty liver disease, diabetes, obesity, and hepatocellular carcinoma. Clin Liver Dis. 2015 May; 19(2):361-79.
    View in: PubMed
    Score: 0.403
  38. NAFLD in 2014: Genetics, diagnostics and therapeutic advances in NAFLD. Nat Rev Gastroenterol Hepatol. 2015 Feb; 12(2):65-6.
    View in: PubMed
    Score: 0.398
  39. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024 02 08; 390(6):497-509.
    View in: PubMed
    Score: 0.187
  40. Implementation of a liver health check in people with type 2 diabetes. Lancet Gastroenterol Hepatol. 2024 Jan; 9(1):83-91.
    View in: PubMed
    Score: 0.186
  41. Utility of pathologist panels for achieving consensus in NASH histologic scoring in clinical trials: Data from a phase 3 study. Hepatol Commun. 2024 Jan 01; 8(1).
    View in: PubMed
    Score: 0.185
  42. Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease. J Hepatol. 2024 Mar; 80(3):419-430.
    View in: PubMed
    Score: 0.184
  43. A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis. Hepatology. 2024 Mar 01; 79(3):674-689.
    View in: PubMed
    Score: 0.182
  44. Reply: NAFLD, MAFLD, or MASLD? Cut the Gordian knot with "Ludwig disease". Hepatology. 2024 Jan 01; 79(1):E5-E6.
    View in: PubMed
    Score: 0.181
  45. A global research priority agenda to advance public health responses to fatty liver disease. J Hepatol. 2023 09; 79(3):618-634.
    View in: PubMed
    Score: 0.179
  46. Natural history of NASH cirrhosis in liver transplant waitlist registrants. J Hepatol. 2023 10; 79(4):1015-1024.
    View in: PubMed
    Score: 0.178
  47. Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study. Hepatology. 2023 10 01; 78(4):1223-1239.
    View in: PubMed
    Score: 0.177
  48. Research Priorities for Precision Medicine in NAFLD. Clin Liver Dis. 2023 05; 27(2):535-551.
    View in: PubMed
    Score: 0.175
  49. The Cost of Diagnosing and Managing Non-alcoholic Steatohepatitis in Europe and the United States. J Gastrointestin Liver Dis. 2022 09 15; 31(3):317-322.
    View in: PubMed
    Score: 0.170
  50. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract. 2022 May; 28(5):528-562.
    View in: PubMed
    Score: 0.165
  51. Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Gastroenterol Hepatol. 2022 07; 7(7):603-616.
    View in: PubMed
    Score: 0.164
  52. Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD. J Hepatol. 2022 05; 76(5):1030-1041.
    View in: PubMed
    Score: 0.162
  53. A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approach. Aliment Pharmacol Ther. 2022 01; 55(2):234-243.
    View in: PubMed
    Score: 0.161
  54. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol. 2022 01; 19(1):60-78.
    View in: PubMed
    Score: 0.160
  55. Preparing for the NASH epidemic: A call to action. Obesity (Silver Spring). 2021 09; 29(9):1401-1412.
    View in: PubMed
    Score: 0.157
  56. Preparing for the NASH Epidemic: A Call to Action. Diabetes Care. 2021 09; 44(9):2162-2172.
    View in: PubMed
    Score: 0.157
  57. Preparing for the NASH Epidemic: A Call to Action. Gastroenterology. 2021 09; 161(3):1030-1042.e8.
    View in: PubMed
    Score: 0.157
  58. TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial. Gastroenterology. 2021 11; 161(5):1475-1486.
    View in: PubMed
    Score: 0.157
  59. Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis. Clin Gastroenterol Hepatol. 2022 09; 20(9):2050-2058.e12.
    View in: PubMed
    Score: 0.156
  60. NAFLD: Reporting Histologic Findings in Clinical Practice. Hepatology. 2021 05; 73(5):2028-2038.
    View in: PubMed
    Score: 0.154
  61. From NAFLD to MAFLD: Implications of a Premature Change in Terminology. Hepatology. 2021 03; 73(3):1194-1198.
    View in: PubMed
    Score: 0.152
  62. Non-alcoholic fatty liver disease: Not time for an obituary just yet! J Hepatol. 2021 04; 74(4):972-974.
    View in: PubMed
    Score: 0.150
  63. Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis. Gastroenterology. 2020 11; 159(5):1985-1987.e4.
    View in: PubMed
    Score: 0.147
  64. Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial. Hepatology. 2020 07; 72(1):58-71.
    View in: PubMed
    Score: 0.146
  65. Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices. Aliment Pharmacol Ther. 2020 08; 52(3):513-526.
    View in: PubMed
    Score: 0.145
  66. Longitudinal Association of Non-Alcoholic Fatty Liver Disease With Changes in Myocardial Structure and Function: The CARDIA Study. J Am Heart Assoc. 2020 02 18; 9(4):e014279.
    View in: PubMed
    Score: 0.142
  67. Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension. Gastroenterology. 2020 04; 158(5):1334-1345.e5.
    View in: PubMed
    Score: 0.140
  68. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019 12 14; 394(10215):2184-2196.
    View in: PubMed
    Score: 0.140
  69. A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial. Contemp Clin Trials. 2020 01; 88:105889.
    View in: PubMed
    Score: 0.139
  70. Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum. Hepatology. 2019 11; 70(5):1841-1855.
    View in: PubMed
    Score: 0.139
  71. Low Awareness of Nonalcoholic Fatty Liver Disease in a Population-Based Cohort Sample: the CARDIA Study. J Gen Intern Med. 2019 12; 34(12):2772-2778.
    View in: PubMed
    Score: 0.138
  72. Liver Transplantation for Nonalcoholic Steatohepatitis: Pathophysiology of Recurrence and Clinical Challenges. Dig Dis Sci. 2019 12; 64(12):3413-3430.
    View in: PubMed
    Score: 0.136
  73. Range of Normal Serum Aminotransferase Levels in Liver Transplant Recipients. Transplant Proc. 2019 Jul - Aug; 51(6):1895-1901.
    View in: PubMed
    Score: 0.136
  74. REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. Contemp Clin Trials. 2019 09; 84:105803.
    View in: PubMed
    Score: 0.136
  75. Sex Hormone-Binding Globulin Levels in Young Men Are Associated With Nonalcoholic Fatty Liver Disease in Midlife. Am J Gastroenterol. 2019 05; 114(5):758-763.
    View in: PubMed
    Score: 0.134
  76. Atrial fibrillation is highly prevalent yet undertreated in patients with biopsy-proven nonalcoholic steatohepatitis. Liver Int. 2019 05; 39(5):933-940.
    View in: PubMed
    Score: 0.131
  77. Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases. Aliment Pharmacol Ther. 2018 10; 48(7):696-703.
    View in: PubMed
    Score: 0.128
  78. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018 07; 24(7):908-922.
    View in: PubMed
    Score: 0.127
  79. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2018 07; 68(1):361-371.
    View in: PubMed
    Score: 0.127
  80. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology. 2018 07; 68(1):349-360.
    View in: PubMed
    Score: 0.127
  81. Randomised clinical trial: a leucine-metformin-sildenafil combination (NS-0200) vs placebo in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2018 06; 47(12):1639-1651.
    View in: PubMed
    Score: 0.125
  82. Twenty-five-year trajectories of insulin resistance and pancreatic ß-cell response and diabetes risk in nonalcoholic fatty liver disease. Liver Int. 2018 11; 38(11):2069-2081.
    View in: PubMed
    Score: 0.125
  83. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2018 03 24; 391(10126):1174-1185.
    View in: PubMed
    Score: 0.124
  84. Body mass index trajectories in young adulthood predict non-alcoholic fatty liver disease in middle age: The CARDIA cohort study. Liver Int. 2018 04; 38(4):706-714.
    View in: PubMed
    Score: 0.121
  85. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018 01; 67(1):328-357.
    View in: PubMed
    Score: 0.120
  86. Testosterone Levels in Pre-Menopausal Women are Associated With Nonalcoholic Fatty Liver Disease in Midlife. Am J Gastroenterol. 2017 05; 112(5):755-762.
    View in: PubMed
    Score: 0.116
  87. Nonalcoholic fatty liver disease. Nat Rev Dis Primers. 2015 12 17; 1:15080.
    View in: PubMed
    Score: 0.106
  88. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: A population-based study. Hepatology. 2015 Sep; 62(3):773-83.
    View in: PubMed
    Score: 0.103
  89. Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events. Hepatology. 2012 Nov; 56(5):1741-50.
    View in: PubMed
    Score: 0.086
  90. A myriad of pathways to NASH. Clin Liver Dis. 2012 Aug; 16(3):525-48.
    View in: PubMed
    Score: 0.084
  91. The role of diet and nutrient composition in nonalcoholic Fatty liver disease. J Acad Nutr Diet. 2012 Mar; 112(3):401-9.
    View in: PubMed
    Score: 0.082
  92. Will the increased prevalence of nonalcoholic steatohepatitis (NASH) in the age of better hepatitis C virus therapy make NASH the deadlier disease? Hepatology. 2011 Oct; 54(4):1118-20.
    View in: PubMed
    Score: 0.079
  93. Dysregulation of the unfolded protein response in db/db mice with diet-induced steatohepatitis. Hepatology. 2011 Nov; 54(5):1600-9.
    View in: PubMed
    Score: 0.078
  94. Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. Ann Hepatol. 2011 Jul-Sep; 10(3):277-86.
    View in: PubMed
    Score: 0.078
  95. Preparing for the NASH epidemic: A call to action. Metabolism. 2021 09; 122:154822.
    View in: PubMed
    Score: 0.039
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.